Novel drug microneedle patch

By combining percutaneous power delivery technology and soluble microneedle patches, the transdermal rate of the drug is improved by using polyimide film and gold microelectrode arrays, and patch contact is improved through airbags and rubber bumps, the solution is solved by loading Chinese medicine microscopes. The problem of low transdermal rate of needles achieves more efficient drug release and patch adhesion effects.

CN221981383UActive Publication Date: 2024-11-12SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202323022995.5
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2023-11-09
Publication Date
2024-11-12
Estimated Expiration
2033-11-09

AI Technical Summary

Technical Problem

The transdermal rate and utilization rate of microneedle loaded with traditional Chinese medicine are low, making it difficult to achieve the best clinical efficacy.

Method used

Combined with percutaneous power delivery technology and drug-loaded soluble microneedle patches, polyimide film, adhesive layer and gold microelectrode arrays, promote drug release through friction currents, and improve patches through airbags and rubber bumps Contact with the skin to avoid bubbles and wrinkles.

Benefits of technology

The transdermal and utilization of drugs are improved, drug release is promoted through local microcurrents, and patch contact with the skin is improved through airbags and rubber bumps, solving the bubble and wrinkle problems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN221981383U_ABST
    Figure CN221981383U_ABST
Patent Text Reader

Abstract

The utility model discloses a novel medicine microneedle patch, which relates to the technical field of microneedles and comprises a polyimide film, a substrate layer is mounted at the bottom of the polyimide film, a bonding layer is mounted at the bottom of the substrate layer, a gelatin layer is fixedly connected to the bottom of the bonding layer, microneedles which are arranged at equal intervals are fixedly connected to the bottom of the gelatin layer, and the microneedles are fixedly connected to the bottom of the bonding layer. A flow guide groove is formed in the microneedle, and a gel layer is installed on the top of the polyimide film. According to the novel medicine microneedle patch provided by the utility model, the polyimide film, the microneedles and the adhesive layer are arranged, so that when a finger slides on the polyimide film from left to right during use, the potential of the right side of the gold microelectrode array patch with the polylactic acid coating is higher than that of the left side due to the transfer of surface charges; therefore, electrons are driven to flow from the left electrode to the right electrode through the skin to serve as an external load, local micro-current is generated, release of the medicine is promoted, and the transdermal rate of the medicine can be increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The utility model relates to the technical field of microneedles, in particular to a novel drug microneedle patch. Background Art

[0002] Microneedle patches are made by attaching micron-level drug microneedles to a piece of film, which is then applied to the skin. The microneedles penetrate the skin surface, release the drug into the subcutaneous layer, and slowly release it over time. This method of drug administration can prevent the drug from being destroyed by digestive acid, while achieving continuous and gradual release of the drug, achieving the ideal therapeutic effect.

[0003] In the existing technology, the transdermal penetration rate and utilization rate of microneedles carrying effective ingredients of traditional Chinese medicine are low. Although the latest microneedle transdermal technology has effectively improved the transdermal penetration rate of some effective ingredients of traditional Chinese medicine, its transdermal drug content and sustained transdermal penetration rate are difficult to achieve the optimal clinical therapeutic effect. Utility Model Content

[0004] In view of the above-mentioned problems of low skin penetration rate and utilization rate of the existing microneedles carrying effective ingredients of traditional Chinese medicine, the present utility model is proposed.

[0005] Therefore, the purpose of the utility model is to provide a new type of drug microneedle patch, which aims to solve the problem of poor transdermal effect of topical drugs for the treatment of atherosclerosis, combine transcutaneous current supply technology with soluble microneedle patches containing drugs for topical treatment to improve transdermal penetration rate and drug utilization rate.

[0006] In order to solve the above technical problems, the utility model provides the following technical solutions: a novel drug microneedle patch, which includes a polyimide film, a substrate layer is installed at the bottom of the polyimide film, an adhesive layer is installed at the bottom of the substrate layer, a gelatin layer is fixedly connected to the bottom of the adhesive layer, microneedles arranged equidistantly are fixedly connected to the bottom of the gelatin layer, a guide groove is opened inside the microneedle, a gel layer is installed on the top of the polyimide film, the polyimide film is used as a triboelectric layer, and the gel layer is made of hydrogel, which acts as an adhesive and can also be used to buffer the vertical pressure of fingertip friction.

[0007] As a preferred embodiment of the novel drug microneedle patch of the utility model, the matrix material of the microneedle is polyvinyl alcohol and polyvinyl pyrrolidone, polylactic acid and the microneedle are first bonded together and then a 50nm gold layer is sprayed on the surface to form a polylactic acid coating, and the gold microelectrode array patch coated with polylactic acid is used as an electrode.

[0008] As a preferred solution of the novel drug microneedle patch of the utility model, the adhesive layer is made of F46 resin, and the surface of the F46 resin film is covered with a polyimide film tape, and the combination of the two can be used as a dielectric layer.

[0009] As a preferred solution of the novel drug microneedle patch of the utility model, a cavity is provided inside the polyimide film, one end of the polyimide film is fixedly connected with an air inlet pipe, and the air inlet pipe is used to connect to an external inflator.

[0010] As a preferred solution of the novel drug microneedle patch of the utility model, an airbag is installed at one end of the polyimide film, and the airbag is located on one side of the air inlet pipe. The airbag can discharge excess air inside the polyimide film to prevent bubbles or wrinkles from forming between the patch and the skin.

[0011] As a preferred solution of the novel drug microneedle patch of the utility model, wherein: the surface of the airbag is fixedly connected with equidistantly arranged rubber bumps, and the rubber bumps can prevent the adaptor from slipping.

[0012] Beneficial effects of the utility model:

[0013] 1. The utility model is provided with a polyimide film, a microneedle and an adhesive layer. When a finger slides from left to right on the polyimide film during use, due to the transfer of surface charge, the potential on the right side of the gold microelectrode array patch coated with polylactic acid is higher than that on the left side, thereby driving electrons to flow from the left electrode through the skin to the right electrode as an external load, generating a local microcurrent, promoting the release of the drug, and thus improving the skin penetration rate of the drug.

[0014] 2. The utility model is provided with an air bag, a rubber bump and an air intake pipe. When in use, first an external inflator is connected to the air intake pipe, and then the inflator is started to inflate air into the interior of the polyimide film to expand the polyimide film. In this process, the air intake pipe is blocked, and then the patch is placed at the position where it needs to be pasted. After the placement is completed, the blockage of the air intake pipe is cancelled, and the gas inside the polyimide film is slowly discharged. Finally, the air bag is squeezed to discharge the remaining gas inside the polyimide film, so that the patch can be better fitted to the skin, further solving the problem that bubbles will be generated when the patch is fitted because the skin is not wiped clean, resulting in loose fitting, and further solving the problem that the patch will be wrinkled. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions of the embodiments of the present utility model, the following briefly introduces the drawings required for the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present utility model. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:

[0016] Figure 1 This is a schematic diagram of the overall structure of the novel drug microneedle patch of the utility model.

[0017] Figure 2 This is a diagram showing the overall structure of the novel drug microneedle patch of the utility model.

[0018] Figure 3 This is a schematic diagram of the cross-sectional structure of the novel drug microneedle patch of the utility model.

[0019] Figure 4 This is a schematic diagram of the current principle of the novel drug microneedle patch of the utility model.

[0020] Description of reference numerals:

[0021] 1. Polyimide film; 2. Base layer; 3. Adhesive layer; 4. Gelatin layer; 5. Microneedle; 6. Gel layer; 7. Guide groove; 8. Cavity; 9. Intake pipe; 10. Airbag; 11. Rubber bump. DETAILED DESCRIPTION

[0022] In order to make the above-mentioned purposes, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the accompanying drawings.

[0023] Example 1

[0024] Reference Figure 1-4 , which is the first embodiment of the utility model, provides a new type of drug microneedle patch, which includes a polyimide film 1, a substrate layer 2 is installed at the bottom of the polyimide film 1, an adhesive layer 3 is installed at the bottom of the substrate layer 2, a gelatin layer 4 is fixedly connected to the bottom of the adhesive layer 3, and microneedles 5 arranged equidistantly are fixedly connected to the bottom of the gelatin layer 4, a guide groove 7 is opened inside the microneedle 5, a gel layer 6 is installed on the top of the polyimide film 1, the matrix material of the microneedle 5 is polyvinyl alcohol and polyvinyl pyrrolidone, and the adhesive layer 3 is made of F46 resin.

[0025] The microneedle matrix material of the soluble microneedle patch is a combination of polyvinyl alcohol and polyvinyl pyrrolidone. The patch has two parts, the inner and outer parts. The inner layer is divided into three layers, a triboelectric layer, a dielectric layer and an electrode layer. The polyimide film 1 is used as the triboelectric layer, and the F46 resin film adhesive layer 3 covered with Kapton tape is used as the dielectric layer. The polylactic acid and the microneedle 5 are first bonded together, and then a 50nm gold layer is sprayed on the surface of the two to form a polylactic acid coating. The gold microelectrode array patch coated with polylactic acid is used as an electrode, and the hydrogel is used as an adhesive, and can also be used to buffer the vertical pressure of fingertip friction.

[0026] The frictional transcutaneous power delivery technology is achieved by friction between the polyimide film 1, the adhesive layer 3 and the microneedle 5 through the fingertips. The specific principle is that when the finger slides from left to right on the polyimide film 1, due to the transfer of surface charge, the potential on the right side of the polylactic acid-coated gold microelectrode array patch is higher than the potential on the left side, thereby driving electrons to flow from the left electrode through the skin to the right electrode as an external load, generating local microcurrent, promoting the release of drugs, and thus improving the drug's skin penetration rate.

[0027] The bonding of the patch is divided into the following steps:

[0028] In the first step, PLA microneedle patches (PLAMNPs) were prepared by forming a 5×5MN array on the patch through a thermoforming process.

[0029] In the second step, a 50 nm thick gold layer was sputtered on the surface of PLA MNP (composite particles composed of polylactic acid and magnetic nanoparticles) to produce PLA-Au MNP (gold-coated polylactic acid microneedles).

[0030] In the third step, drug-loaded cGe l-cHA MNs (drug-loaded layer) with a length of 550 μm were prepared by vacuum extraction and covered on the tip of PLA-Au MNs (polylactic acid-gold nanoparticle composites) to fabricate two-stage PLA-Au / cGe l-cHA CMNPs (polylactic acid-gold / collagen-hyaluronic acid magnetic composite nanoparticles).

[0031] The patch is combined in several steps:

[0032] The first step is to prepare blank microneedles. Take 500 mg CS (gelatin) and 100 mg HPMC (hydroxypropyl methylcellulose) in a beaker, add 1.2 mL of water and mix well. After sufficient swelling, pour it into a microneedle mold and centrifuge it at 4000 r / min for 15 min. Scrape off the matrix liquid on the surface of the mold and keep only the needle tip. Place it in a dryer and dry it for 10 hours to make blank microneedles.

[0033] In the second step, a PLA MN patch was prepared by a thermoforming process (forming a 5 × 5 MN array on a 7 × 7 mm patch), and then a PLA MN patch with a gold-containing layer was produced by sputtering a 50 nm thick gold layer on the surface of the PLA MN patch.

[0034] The third step is to prepare a drug-carrying layer with a length of 550 μm by vacuuming (vacuuming is performed to allow the drug-carrying layer and the microneedles to fit together). When used, the current generated by the polyimide film 1 can be introduced through the polylactic acid gold-containing layer microneedles to form transcutaneous low-frequency electrical stimulation and deliver the drug directly into the skin through the drug-carrying layer.

[0035] In the fourth step, the polyimide film 1 and the prepared drug-loaded polylactic acid microneedles 5 are combined via an F46 resin film with Kapton tape to form a three-layer structure.

[0036] Example 2

[0037] Reference Figure 1-4 , which is the second embodiment of the utility model, and this embodiment is different from the first embodiment in that:

[0038] A cavity 8 is opened inside the polyimide film 1, one end of the polyimide film 1 is fixedly connected to an air intake pipe 9, an airbag 10 is installed at one end of the polyimide film 1, the airbag 10 is located on one side of the air intake pipe 9, and the surface of the airbag 10 is fixedly connected to equidistantly arranged rubber bumps 11.

[0039] During use, first use an external inflator to connect to the air inlet pipe 9, then start the inflator to inflate the inside of the polyimide film 1 to expand the polyimide film 1. In this process, the air inlet pipe 9 is blocked, and then the patch is placed at the position where it needs to be pasted. After the placement is completed, the blockage of the air inlet pipe 9 is removed, and the gas inside the polyimide film 1 will be slowly discharged. Finally, the airbag 10 is squeezed to discharge the remaining gas inside the polyimide film 1, so that the patch can fit the skin better, further solving the problem of bubbles caused by not wiping the skin clean and causing loose fitting when the patch is fitted, and further solving the problem of wrinkles on the patch.

[0040] The remaining structures are the same as those of Example 1.

[0041] It should be noted that the above embodiments are only used to illustrate the technical solution of the utility model rather than to limit it. Although the utility model has been described in detail with reference to the preferred embodiments, ordinary technicians in the field should understand that the technical solution of the utility model can be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the utility model, which should be included in the scope of the claims of the utility model.

Claims

1. A novel drug microneedle patch, comprising a polyimide film (1), characterized in that: A substrate layer (2) is installed at the bottom of the polyimide film (1), an adhesive layer (3) is installed at the bottom of the substrate layer (2), a gelatin layer (4) is fixedly connected to the bottom of the adhesive layer (3), microneedles (5) arranged equidistantly are fixedly connected to the bottom of the gelatin layer (4), a flow guide groove (7) is provided inside the microneedles (5), and a gel layer (6) is installed on the top of the polyimide film (1).

2. The novel drug microneedle patch according to claim 1, characterized in that: The matrix material of the microneedle (5) is polyvinyl alcohol and polyvinyl pyrrolidone.

3. The novel drug microneedle patch according to claim 2, characterized in that: The adhesive layer (3) is made of F46 resin.

4. The novel drug microneedle patch according to claim 3, characterized in that: A cavity (8) is provided inside the polyimide film (1), and an air inlet pipe (9) is fixedly connected to one end of the polyimide film (1).

5. The novel drug microneedle patch according to claim 4, characterized in that: An air bag (10) is installed at one end of the polyimide film (1), and the air bag (10) is located on one side of the air intake pipe (9).

6. The novel drug microneedle patch according to claim 5, characterized in that: The surface of the airbag (10) is fixedly connected with rubber bumps (11) arranged at equal distances.